Empagliflozin: Reimbursement Recommendation

More on Chronic kidney disease

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Physical performance links to heart failure and death in CKD

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Underweight carries higher kidney risk than excess adiposity

  Frontiers in Endocrinology · 4 Oct 2026

• GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD

  Diabetes, Obesity & Metabolism · 4 Oct 2026